Gamma-modified Peptide Nucleic Acid (γPNA1) targets VEGFA genomic DNA to inhibit solid tumor growth and improve survival.

The Vascular Endothelial Growth Factor A (VEGFA) gene is a pivotal regulator of cellular proliferation, neovascularization, and tumorigenic progression in solid tumors. Under hypoxic conditions prevalent in the tumor microenvironment, Hypoxic Inducible Factor-1 (HIF-1α and HIF-1β) heterodimers bind to the Hypoxic Responsive Element (HRE) on the VEGFA gene, initiating its upregulation. Current anti-angiogenic strategies often target VEGFA protein or its receptor, but a significant therapeutic gap exists in directly preventing its transcription at the genomic level, which could offer a more fundamental and precise control over tumor growth.

Researchers developed a next-generation gamma-modified Peptide Nucleic Acid (γPNA), specifically γPNA1, designed for sequence-specific targeting of VEGFA genomic DNA. This intervention aimed to prevent HIF-1 heterodimer interaction with the HRE on the VEGFA gene. The efficacy of γPNA1 was first confirmed in a series of solid cancer cell lines using gene expression analysis, Western blot analysis, and cell viability-based functional studies. Subsequently, preclinical testing was conducted in xenograft mouse models of triple-negative breast cancer (TNBC) to evaluate its in vivo effects on tumor progression. Specific dosing, route, frequency, and duration details were not provided in the abstract.

The study successfully demonstrated that γPNA1 achieves sequence-specific targeting of VEGFA genomic DNA, effectively preventing the binding of HIF-1 heterodimers to the HRE and subsequently silencing VEGFA expression. This genomic targeting strategy was confirmed to be efficacious across multiple solid tumor cell lines, as evidenced by reduced VEGFA gene expression, decreased VEGFA protein levels, and impaired cell viability. The most impactful finding emerged from the in vivo studies:

In xenograft mouse models of triple-negative breast cancer (TNBC), targeting VEGFA genomic DNA with γPNA1 resulted in a notable decrease in tumor growth and a significant increase in survival rates in the treated mice. These results underscore the potential of this novel approach to directly suppress VEGFA transcription and control tumor progression.